Background And Objectives: Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Little is known about cardiovascular risk factors in patients with PCOS. We investigated plasma markers of cardiovascular disease in Saudi women with PCOS, with an emphasis on asymmetric dimethylarginine (ADMA) and total homocysteine (tHcy).
Patients And Methods: Fifty Saudi women with PCOS diagnosed by the Rotterdam criteria (mean age [SD] 30.2 [3.0] years) and 40 controls without PCOS (mean age 29.3 [2.5] years) had measyrements taken of clinical, metabolic, and hormonal parameters, including plasma ADMA, tHcy, lipoprotein (a) ([Lp(a)], and serum high sensitivity C-reactive protein (hs-CRP), nitric oxid, and fibrinogen. Insulin resistance was calculated by the homeostasis model assessment (HOMA-IR).
Results: Women with PCOS had significantly higher fasting insulin, HOMA-IR, and luteinizing hormone (LH) levels than healthy controls (P P P CONCLUSION: Our study revealed that Saudi women with PCOS had a significantly different levels of plasma markers of cardiovascular disease compared with normal controls. Therefore, clinicians who manage women with PCOS should follow up on these markers to reduce the risk of cardiovascular disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931778 | PMC |
| http://dx.doi.org/10.4103/0256-4947.65255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the effects of time-restricted eating on overweight and obese women with polycystic ovary syndrome: A randomized controlled trial study protocol.
PLoS One
January 2025
School of Nursing, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Background: Time-restricted eating (TRE) manages weight effectively, but choosing how long and what time window remain debatable. Although an 8:00 a.m.
View Article and Find Full Text PDFBody shape concerns, sexual satisfaction, and associated factors among patients with polycystic ovarian syndrome: A cross-sectional study in Western Saudi Arabia.
Saudi Med J
January 2025
From the Department of Family and Community Medicine (Alsaidan, Thirunavukkarasu), College of Medicine, Jouf University, Aljouf; and from the Department of Public Health (Alsulami), Maternity and Children Hospital, Makkah, Kingdom of Saudi Arabia.
Objectives: To determine body shape concerns (BSCs), sexual satisfaction, and associated factors in patients with polycystic ovarian syndrome (PCOS).
Methods: Using a structured and validated questionnaire, a cross-sectional survey was carried out at the Maternity and Children's Hospital in Makkah, Saudi Arabia. Data were collected between August 2023 and June 2024.
Screening of serum biomarkers in patients with PCOS through lipid omics and ensemble machine learning.
PLoS One
January 2025
Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen, China.
Polycystic ovary syndrome (PCOS) is a primary endocrine disorder affecting premenopausal women involving metabolic dysregulation. We aimed to screen serum biomarkers in PCOS patients using untargeted lipidomics and ensemble machine learning. Serum from PCOS patients and non-PCOS subjects were collected for untargeted lipidomics analysis.
View Article and Find Full Text PDFPurpose: Polycystic Ovary Syndrome (PCOS) and Adrenal hyperplasia (CAH) are two pathologic conditions sharing several clinical features (hirsutism, acne, polycystic ovary morphology, metabolic alterations, ovulatory dysfunctions) and especially hyperandrogenism as a common clinical hallmark. Therefore, making a differential diagnosis of the two conditions still remains a great medical challenge.
Methods: In particular, the comparison discussed in this review referred to non-classical form of adrenal hyperplasia (NCAH), which regards the adult population, and the Endocrine Metabolic Syndrome (EMS), following the new set of PCOS diagnostic criteria proposed by the Experts Group on Inositol and Clinical Research, and on PCOS (EGOI-PCOS).
Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease.
Pharmaceutics
December 2024
School of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming 650500, China.
Polycystic ovary syndrome (PCOS) is the predominant endocrine disorder among women of reproductive age and represents the leading cause of anovulatory infertility, which imposes a considerable health and economic burden. Currently, medications used to treat PCOS can lead to certain adverse reactions, such as affecting fertility and increasing the risk of venous thrombosis. Drug delivery systems utilizing nanomaterials, characterized by prolonged half-life, precision-targeted delivery, enhanced bioavailability, and reduced toxicity, are currently being employed in the management of PCOS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!